Carbon Monoxide

Varma, Daya R.; Mulay, Shree; Chemtob, Sylvain

doi:10.1016/b978-0-12-800159-2.00021-x

Cited by 4 publications

(2 citation statements)

References 224 publications

(298 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The severity of CO poisoning varies according to the exposure concentration and duration of CO which can be reflected by the COHb level. Mild symptoms can manifest between 10 and 20% COHb, and death can occur at COHb greater than 60% [ 31 ]. However, the histopathology and clinical course of CO poisoning is yet properly advocated by the COHb theory only.…”

Section: Carbon Monoxide: From Killer To Healermentioning

confidence: 99%

“…Since then, we have been witnessing the explosion in the quantity and quality of studies of the actions of CO in mammalian systems. More than 75% of CO produced in human body arises from the erythrocyte turnover [ 36 ], while a small fraction (20%) originates from other hemoproteins such as myoglobin and iron-containing enzymes [ 31 ]. CO is generally produced at very low levels during the metabolism in healthy adults that result in the background COHb concentration in blood of approximately 0.5–0.8% [ 37 ].…”

Section: Carbon Monoxide: From Killer To Healermentioning

confidence: 99%

See 1 more Smart Citation

The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine

Tuan

et al. 2021

Redox Biology

View full text Add to dashboard Cite

Carbon monoxide (CO) is now well recognized a pivotal endogenous signaling molecule in mammalian lives. The proof-of-concept employing chemical carriers of exogenous CO as prodrugs for CO release, also known as CO-releasing molecules (CO-RMs), has been appreciated. The major advantage of CO-RMs is that they are able to deliver CO to the target sites in a controlled manner. There is an increasing body of experimental studies suggesting the therapeutic potentials of CO and CO-RMs in different cancer models. This review firstly presents a short but crucial view concerning the characteristics of CO and CO-RMs. Then, the anticancer activities of CO-RMs that target many cancer hallmarks, mainly proliferation, apoptosis, angiogenesis, and invasion and metastasis, are discussed. However, their anticancer activities are varying and cell-type specific. The aerobic metabolism of molecular oxygen inevitably generates various oxygen-containing reactive metabolites termed reactive oxygen species (ROS) which play important roles in both physiology and pathophysiology. Although ROS act as a double-edged sword in cancer, both sides of which may potentially have been exploited for therapeutic benefits. The main focus of the present review is thus to identify the possible signaling network by which CO-RMs can exert their anticancer actions, where ROS play the central role. Another important issue concerning the potential effect of CO-RMs on the aerobic glycolysis (the Warburg effect) which is a feature of cancer metabolic reprogramming is given before the conclusion with future prospects on the challenges of developing CO-RMs into clinically pharmaceutical candidates in cancer therapy.

show abstract

Section: Carbon Monoxide: From Killer To Healermentioning

confidence: 99%

Section: Carbon Monoxide: From Killer To Healermentioning

confidence: 99%